dendreon, page-12

====Dendreon: Targeting Cancer, Transforming Lives
--Summary of Phase 3 IMPACT Trial Results Presented at AUA Meeting, Webcast Conference Call,
--April 28, 2009

http://files.shareholder.com/downloads/DNDN/617742340x0x290327/0d56dd47-8426-46dd-ab31-705983b009ca/DNDN_42809_IMPACT_Webcast_Slides_FINAL.pdf

===PROVENGE===
Sipuleucel-T is an autologous active cellular immunotherapy that activates the immune system against prostate cancer
(wli: it is similar to the CVav of PRR functionally)

===Randomized Phase 3 IMPACT Trial===
(IMmunotherapy Prostate AdenoCarcinoma Treatment)

===Four stages for Phase III trials===
--Stage 1
Asymptomatic or Minimally
Symptomatic
Metastatic
Androgen Independent
Prostate Cancer
(N=512)(wli: 512 patients)

**Part one of stage 2
Sipuleucel-T
Q 2 weeks x 3

**Part Two of stage 2
Placebo
Q 2 weeks x 3

--Stage three
PROGRESSION

**Part One of Stage three

Treated at Physician Discretion

**Part two of Stage Four

Treated at Physician discretion and/or Salvage Protocol

--Stage four
SURVIVAL

===========================================
====Primary endpoint:====
Overall Survival
====Secondary endpoint:===
Time to Objective Disease Progression